The local medical sector is excited with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for managing obesity. This https://ilovebookmarking.com/story21770333/the-new-retatrutide-australia-a-potential-hope-for-obesity-treatment